Immune checkpoint inhibitors combined with chemotherapy/bevacizumab therapy for patients with advanced lung cancer and heavily treated with EGFR mutation: a retrospective analysis

BACKGROUND: EGFR-mutated lung cancer poorly responded to anti-programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) monotherapy. Whether patients with EGFR-mutated lung cancer can benefit from anti-PD-1/PD-L1 therapy combined with other drugs remains controversial. We retrospectively evaluated...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Ran, Zhao, Zhiting, Shi, Yue, Shi, Meiqi, Xia, Guohao, Yu, Shaorong, Feng, Jifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8182551/
https://www.ncbi.nlm.nih.gov/pubmed/34164187
http://dx.doi.org/10.21037/jtd-20-3520

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8182551/
https://www.ncbi.nlm.nih.gov/pubmed/34164187
http://dx.doi.org/10.21037/jtd-20-3520

Ejemplares similares